Report Id: SNS/HC/1753 | June 2022 | Region: Global | 125 Pages
Report Scope & Overview:
The Biobanking Market Size was valued at USD 45.262 billion in 2021, and is expected to reach USD 75.092 billion by 2028, and grow at a CAGR of 7.5% over the forecast period 2022-2028.
A biobank is a form of biorepository that holds biological samples for research purposes. Biobanks have become a valuable resource in medical research, supporting a wide range of modern studies such as genomics and customised medicine. Scientists can use biobanks to gain access to data from a large number of people. Materials from Biobanks and data derived from those samples are frequently used by several researchers for research purposes. Biobanks are collections of human biological materials such as plasma, pure DNA, blood, saliva, and other biospecimens that are stored, distributed, and collected in one location.
Biobanks assist in the storage of a patient's personal and medical information. Maintaining biobanks for preserving biological resources necessitates a suitable environment. These materials and data are used to diagnose diseases and determine their causes. Many disorders, for example, are linked to single-nucleotide polymorphism. The registration of each sample entering and exiting the systems are saved centrally, generally on a computer system that can be regularly backed up. Existing systems are compact, keeping approximately 41,000 samples in less than a quarter of the space required by a -81°C freezer. For the sake of security, copy tests are habitually kept in a different spot.
Biobanking advancements and the rising prevalence of saving newborns' cord blood stem cells
The demand for low-cost drug discovery and development is growing.
Supporting Regenerative Medicine Research with Public and Private Funding
Intensification of disease-related genomic research
Problems in Obtaining Biospecimen Samples
Automation's High Costs
Rising Interest in Cell Therapy Research and Development
Biobanks' Long-Term Viability
IMPACT OF COVID-19
The coronavirus, also known as the Covid 19 pandemic, had a negative effect on the biobanking industry, as the growing numbers of Covid cases has raised concerns about the risks associated with storage, collection, and processing of human biospecimens and all biological materials, as larger transmission of viruses and other diseases would result during the pandemic period. Several biobanking firms that were still collecting human cell and tissue samples saw the implications when the samples for cancer treatment were discovered to be infected with SARS CoV-2 and had become a carrier of the lethal virus, which has become a threat to most biobanking organisations.
Be that as it may, then again, different advances have been taken and assets have been used to frame structures at low levels to gather tests of SARS Cov-2 from a huge base of populace and to control what is happening of the pandemic through the improvement of immunizations and to give an exploration base to all genomic investigates and advancement of medical care frameworks.
By Specimen type
Due to a growth in the incidence of hematological illnesses, a rise in demands for blood products for collecting specimens, and a rise in accidents, the blood products sector dominated the market in 2020 and is probably going to proceed with this pattern during the estimate time frame. Moreover, due to an increase in demand for regenerative medicines, an increase in the prevalence of cardiovascular and neurological illnesses, and a surge in the requirement for organ storage for transplant, the solid tissue segment is likely to develop significantly throughout the forecast period.
By Application type
According to the rise in the number of chronic diseases and breakthroughs in tissue regeneration, the research sector dominated the market in 2021 and is likely to do so throughout the forecast period. The therapeutic segment, on the other hand, is predicted to develop significantly over the projection period, owing to an increase in the frequency of chronic diseases and trauma crises, as well as an expansion in the occurrence of degenerative illnesses and a shortage of organs for transplantation.
Real biobanks and virtual biobanks have now been added to the worldwide market. In 2021, physical/real biobanks dominated the market, accounting for 80.4 percent of total revenue. These biobanks have a well-established network and so control a large portion of the revenue pie. The biobanks' new working model can be credited with rapid advancement in the realms of bioinformatics analysis and precision medicine. Tissue banks account for the greatest share of tissue banks in 2021, thanks to a significant collection of tissue samples collected over time from pathological labs, therapeutic trials, and research projects.
Biobanking & repository, lab processing, qualification/validation, cold chain logistics, and other services have all been sub-segmented into the global market. In 2021, the biobanking and repository services category dominated the market, accounting for around 38.00% of total revenue. This is due to the rising need for bio sample preservation in order to develop precision medicine and disease-specific research, as well as the increased market penetration of these services. The segment has benefited from the spread of biobanking services from university research to clinical enterprises and government efforts, as well as highly-connected and open-ended ventures.
Some of the major key players are as follows: Avantor, BioCision, Becton, Dickinson and Company (BD), Danaher Corporation, Hamilton Company, Merck KGaA, QIAGEN, Thermo Fisher Scientific, Inc., Tecan Trading AG., Taylor-Wharton.
By Specimen type
Cold Chain Logistics
Biobanking & Repository
By Application type
By End User
Pharma & Biotech Companies
North America, Europe, Asia Pacific, and the Rest of the World are the regions that make up the global biobanking market. Over the projected period, North America is expected to dominate the Biobanking market, followed by Europe and Asia Pacific. In contrast, due to the expanding healthcare and diagnostics infrastructure across the region, Asia Pacific is predicted to develop at the fastest CAGR.
Rest of Europe
Rest of Asia-Pacific
The Middle East & Africa
Rest of Middle East & Africa
Rest of Latin America
|Market Size in 2021||US$ 45.262 Billion|
|Market Size by 2028||US$ 75.092 Billion|
|CAGR||CAGR of 7.5% From 2022 to 2028|
|Report Scope & Coverage||Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook|
|Key Segments||• By Specimen type (Solid Tissue, Nucleic Acid, Cell Lines, Blood Products, Others)
• By Type (Disease-oriented, Population)
• By Service (Qualification/ Validation, Cold Chain Logistics, Biobanking & Repository, Lab processing, Other Services)
• By Application Type (Research, Therapeutic)
• By End User (Pharma & Biotech Companies, Academic Institutions)
|Regional Analysis/Coverage||North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
|Company Profiles||Avantor, BioCision, Becton, Dickinson and Company (BD), Danaher Corporation, Hamilton Company, Merck KGaA, QIAGEN, Thermo Fisher Scientific, Inc., Tecan Trading AG., Taylor-Wharton.|
|DRIVERS||• Biobanking advancements and the rising prevalence of saving newborns' cord blood stem cells
• The demand for low-cost drug discovery and development is growing.
• Supporting Regenerative Medicine Research with Public and Private Funding
|OPPORTUNITIES||• Problems in Obtaining Biospecimen Samples
• Automation's High Costs
Frequently Asked Questions (FAQ) :
Top-down, bottom-up, Quantitative, Qualitative Research, Descriptive, Analytical, Applied, Fundamental Research.
Disease-oriented, and Population are the sub segments of by type.
Key drivers of the Pet Oral Care Products Market the demand for low-cost drug discovery and development is growing, and Supporting Regenerative Medicine Research with Public and Private Funding.
Segments of Biobanking market are By Specimen type, By Type, By Service, By Application type, and By End User.
Biobanking Market Size was valued at USD 45.262 billion in 2021 and expected to reach USD 75.092 billion by 2028, and grow at a CAGR of 7.5% over the forecast period 2022-2028.
Table of Contents
1.1 Market Definition
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
4. Impact Analysis
4.1 COVID 19 Impact Analysis
4.2 Impact of Ukraine ware
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Biobanking Market Segmentation, By Specimen Type
8.1 Solid Tissue
8.2 Nucleic Acid
8.3 Cell Lines
8.4 Blood Products
9. Biobanking Market Segmentation, By Type
10. Biobanking Market Segmentation, By Service
10.1 Qualification/ Validation
10.2 Cold Chain Logistics
10.3 Biobanking & Repository
10.4 Lab processing
10.5 Other Services
11. Biobanking Market Segmentation, By Application Type
12. Biobanking Market Segmentation, By End User
12.1 Pharma & Biotech Companies
12.2 Academic Institutions
13. Regional Analysis
13.2 North America
13.3.6 The Netherlands
13.3.7 Rest of Europe
13.4.2 South Korea
13.4.6 Rest of Asia-Pacific
13.5 The Middle East & Africa
13.5.3 South Africa
13.6 Latin America
13.6.3 Rest of Latin America
14 Company Profiles
14.1.2 Products/ Services Offered
14.1.3 SWOT Analysis
14.1.4 The SNS view
14.4 Dickinson and Company (BD)
14.5 Danaher Corporation
14.6 Hamilton Company
14.7 Merck KGaA
14.9 Thermo Fisher Scientific, Inc.
14.10 Tecan Trading AG.
15 Competitive Landscape
15.1 Competitive Benchmark
15.2 Market Share analysis
15.3 Recent Developments
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.